相关实验视频

Updated: Jul 26, 2025

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

HLA-DQA1*05基因型不会影响对乌斯特基努马布和维多利祖马布的临床反应

Pilar Navajas Hernández¹, Pilar Del Pino Bellido², Laura Lorenzo González³

¹Aparato Digestivo, Hospital Universitario Virgen Macarena, España.

Revista espanola de enfermedades digestivas

|June 14, 2023

概括

与抗TNF药物在炎症性肠病 (IBD) 的有效性降低相关的HLA-DQA1*05等位基因不影响对ustekinumab和vidolizumab等新疗法的反应. 这一发现为IBD治疗策略提供了新的希望.

科学领域:

免疫遗传学免疫遗传学
胃肠病学胃肠病学
药物基因组学药物基因组学

背景情况:

抗药抗体降低了抗TNF治疗炎症性肠病 (IBD) 的疗效.
HLA-DQA1*05等位基因与抗TNF药物免疫性风险增加两倍有关.
HLA-DQA1*05对IBD较新的生物疗法的影响仍未得到充分研究.

研究的目的:

研究HLA-DQA1*05等位基因与IBD患者对乌斯特基努马布和维多利祖马布的治疗反应之间的关联.
确定HLA-DQA1*05等位基因是否影响接受这些新生物制剂的患者的疾病活性或治疗结果.

主要方法:

对93名IBD患者进行了回顾性队列研究,这些患者接受了乌斯特基努马布 (n=39) 或韦多利祖马布 (n=54) 治疗.
在6个月,12个月,18个月和24个月使用验证的疾病活性指数 (Harvey-Bradshaw和Mayo得分) 评估治疗反应和缓解.
基因型为存在HLA-DQA1*05等位基因的患者.

主要成果:

这种HLA-DQA1*05等位基因在35.9%的ustekinumab治疗患者和38.9%的vedolizumab治疗患者中存在.
临床响应率在任何治疗组中都没有受到HLA-DQA1*05等位基因存在的显著影响.
没有观察到HLA-DQA1*05和ustekinumab或vidolizumab的有效性降低之间的相关性.

结论:

与抗TNF药物不同,HLA-DQA1*05等位基因似乎不会对乌斯特基努马布和维多利祖马布在IBD治疗中的有效性产生负面影响.
这些发现表明,HLA-DQA1*05状态可能不是选择乌斯特基努马布或维多利祖马布用于IBD治疗的关键因素.
进一步的研究可以探索与特定遗传标记相关的这些较新的生物制剂的免疫性潜力.

更多相关视频

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Factors Affecting Drug Response: Overview

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...